An analysis of the evidence underpinning the national comprehensive cancer network practice guidelines
Mitchell Love1, Jordan Staggs1, Corbin Walters1
1Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, OK, United States; Department of School of Educational Foundations, Leadership And Aviation, Oklahoma State University, Tulsa, OK, United States.
Objective:
This study assesses the quality and completeness of systematic reviews (SRs) included by the National Comprehensive Cancer Network (NCCN) cancer screening clinical practice guidelines (CPGs).
Methods:
We evaluated SRs according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) and AMSTAR-2 (A Measurement Tool to Assess systematic Reviews).
Results:
Seven NCCN CPGs were included with 109 SRs. The mean PRISMA percent completeness of included SRs was 71 % (range 0.1-1.0). The mean AMSTAR-2 percent completeness was 56 % (range 0.05-0.99). Of the 70 SRs assessed via AMSTAR-2, 42 (60 %) received a "critically low" rating, 11 (15.7 %) received "low" ratings, and 17 (24.3 %) received "moderate". None of the SRs received a "high" rating.
Conclusion:
Lack of adherence to AMSTAR-2 and PRISMA reporting standards among the SRs included is prevalent. We suggest improved reporting of SR inclusion criteria and evaluation to bolster the reporting quality of SRs underpinning CPG recommendations.
More Related Videos
Related Concept Videos
Cancer Survival Analysis
Standards of Care II
Standards of Care I
Cancer Prevention
Some...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Nursing Interventions II: Selecting and Classifying the Nursing Interventions


